Skip to main content

Site notifications

CIMZIA (UCB Australia Pty Ltd)

Product name
CIMZIA
Date registered
Evaluation commenced
Decision date
Approval time
240 working days (255)
Active ingredients
certolizumab pegol
Registration type
EOI
Indication
Plaque psoriasis

CIMZIA (solution for injection) is now also indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Help us improve the Therapeutic Goods Administration site